Tests AZD1163 in adults with moderately to severely active rheumatoid arthritis
Tests the drug AZD1163 against a placebo in adults with active rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Key facts
- Where
- Chihuahua City, Estado de México, Guadalajara, Gustavo A. Madero, Mérida, Mexicali, Mexico City, Monterrey, and San Luis Potosí City, MexicoSee the 9 sites
- Phase
- Phase 2
Where in Mexico
- Chihuahua CityChihuahua City, MexicoTaking people
- Estado de MéxicoEstado de México, MexicoNot yet recruiting
- GuadalajaraGuadalajara, MexicoNot yet recruiting
- Gustavo A. MaderoGustavo A. Madero, MexicoNot yet recruiting
- MéridaMérida, MexicoNot yet recruiting
- MexicaliMexicali, MexicoNot yet recruiting
- Mexico CityMexico City, MexicoTaking people
- MonterreyMonterrey, MexicoNot yet recruiting
- San Luis Potosí CitySan Luis Potosí City, MexicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07276581
- Record updated
- 9 October 2026
- Original description
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.Read full original descriptionShow less
A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Inclusion; Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening; Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal; Have a positive ACPA at screening; A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi; A history of at least 12 weeks treatment and >= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation; Exclusion; History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible; Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.